Correction: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin
نویسنده
چکیده
GC has served as an expert witness for plaintiff lawyers preparing hormone therapy litigation. GC has received research support from GlaxoSmithKline, from the American Cancer Society, and from the Breast Cancer Research Foundation. No group or organization funded this manuscript.
منابع مشابه
Estrogen, estrogen plus progestin therapy, and risk of breast cancer.
Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas c...
متن کاملEstrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
CONTEXT In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously ...
متن کاملNew-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
BACKGROUND Estrogen plus progestin therapy increases breast cancer incidence and breast tenderness. Whether breast tenderness during estrogen plus progestin therapy is associated with breast cancer risk is uncertain. METHODS We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated eq...
متن کاملInfluence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
CONTEXT The Women's Health Initiative trial of combined estrogen plus progestin was stopped early when overall health risks, including invasive breast cancer, exceeded benefits. Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography. OBJECTIVE To determi...
متن کاملBreast cancer after use of estrogen plus progestin in postmenopausal women.
BACKGROUND Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Breast Cancer Research : BCR
دوره 9 شماره
صفحات -
تاریخ انتشار 2007